Weighted Average Number of Shares Outstanding, Basic of Esperion Therapeutics, Inc. from 31 Mar 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Esperion Therapeutics, Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Mar 2018 to 31 Dec 2025.
  • Esperion Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 207,865,080, a 11% increase year-over-year.
  • Esperion Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2025 was 207,865,080, a 11% increase from 2024.
  • Esperion Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 187,181,856, a 82% increase from 2023.
  • Esperion Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 103,106,616, a 55% increase from 2022.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Esperion Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 207,865,080 +20,683,224 +11% 01 Oct 2025 31 Dec 2025 10-K 10 Mar 2026 2025 FY
Q3 2025 200,736,136 +5,805,306 +3% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 197,546,239 +8,752,423 +4.6% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 196,127,948 +26,869,384 +16% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 187,181,856 +84,075,240 +82% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2026 2025 FY
Q3 2024 194,930,830 +83,061,352 +74% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 188,793,816 +79,549,971 +73% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 169,258,564 +90,818,298 +116% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 103,106,616 +36,699,374 +55% 01 Oct 2023 31 Dec 2023 10-K 10 Mar 2026 2025 FY
Q3 2023 111,869,478 +44,063,186 +65% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 109,243,845 +46,016,439 +73% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 78,440,266 +17,485,511 +29% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 66,407,242 +37,504,735 +130% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2025 2024 FY
Q3 2022 67,806,292 +41,351,083 +156% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 63,227,406 +37,002,333 +141% 01 Apr 2022 30 Jun 2022 10-Q 01 Aug 2023 2023 Q2
Q1 2022 60,954,755 +34,962,938 +135% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 28,902,507 +2,019,677 +7.5% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2023 2022 FY
Q3 2021 26,455,209 -1,375,072 -4.9% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 26,225,073 -1,440,655 -5.2% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 25,991,817 -1,527,412 -5.6% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 26,882,830 -488,237 -1.8% 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2021 2020 FY
Q3 2020 27,830,281 +658,512 +2.4% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 27,665,728 +696,910 +2.6% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 27,519,229 +676,444 +2.5% 01 Jan 2020 31 Mar 2020 10-K 23 Feb 2021 2020 FY
Q4 2019 27,371,067 01 Oct 2019 31 Dec 2019 10-K 23 Feb 2021 2020 FY
Q3 2019 27,171,769 01 Jul 2019 30 Sep 2019 10-K 23 Feb 2021 2020 FY
Q2 2019 26,968,818 +182,022 +0.68% 01 Apr 2019 30 Jun 2019 10-K 23 Feb 2021 2020 FY
Q1 2019 26,842,785 +237,596 +0.89% 01 Jan 2019 31 Mar 2019 10-K 23 Feb 2021 2020 FY
Q2 2018 26,786,796 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 26,605,189 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1

Esperion Therapeutics, Inc. Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 207,865,080 +20,683,224 +11% 01 Jan 2025 31 Dec 2025 10-K 10 Mar 2026 2025 FY
2024 187,181,856 +84,075,240 +82% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2026 2025 FY
2023 103,106,616 +36,699,374 +55% 01 Jan 2023 31 Dec 2023 10-K 10 Mar 2026 2025 FY
2022 66,407,242 +37,504,735 +130% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2025 2024 FY
2021 28,902,507 +1,428,634 +5.2% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2023 2022 FY
2020 27,473,873 +383,589 +1.4% 01 Jan 2020 31 Dec 2020 10-K 22 Feb 2022 2021 FY
2019 27,090,284 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.